Hematology · 2 h ago
CX-5461 and CDK inhibition show preclinical activity in acute myeloid leukemia
A preclinical study tested CX-5461 with cyclin-dependent kinase inhibitors in human AML cell lines, mouse models and primary patient samples. Dinaciclib enhanced antileukemic activity, but clinical efficacy and safety of the combination remain unestablished.
- Dinaciclib enhanced CX-5461 activity in preclinical AML models.
- Combination treatment prolonged mouse survival and reduced patient-sample colony formation.
- Clinical efficacy and combination safety in AML remain unestablished.
A study published in Leukemia investigated combined inhibition of ribosome biogenesis and cyclin-dependent kinases (CDKs) in acute myeloid leukemia (AML). Researchers used a compound screen in A549 lung carcinoma cells to identify potential partners for CX-5461, then evaluated combinations in AML cell lines, randomized mouse experiments and colony-forming assays using patient-derived bone marrow cells. Sample sizes were not provided in the supplied text.
The screen identified dinaciclib and flavopiridol as synergistic partners. CX-5461 plus dinaciclib showed synergy across genetically diverse AML cell lines, significantly prolonged survival in mouse AML models and reduced colony formation in primary human AML samples. Numerical effect estimates were not available in the supplied material. Both agents stabilized p53: dinaciclib primarily induced rapid apoptosis, whereas CX-5461 mainly promoted cell-cycle arrest. The authors attributed synergy partly to enhanced nucleolar surveillance pathway activation.
These findings support further investigation of the combination rather than clinical use. The evidence is preclinical; previous phase I experience with CX-5461 in other cancers does not establish the combination’s safety or efficacy in AML.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Leukemia: Novel RNA polymerase I and cyclin-dependent kinase combination therapy for the treatment of aggressive acute myeloid leukemia ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.